Accelerating Genomic Biomarker Translation
Cancer patients’ need innovative medicines more than ever, and they require personalised therapies specific to their unique biology fast. Together, international partners such as Illumina and Almac can get pharmaceutical pipelines ready quickly for global oncology clinical trials.
Utilising comprehensive genomic panels that can test for multiple biomarkers at the same time, whilst maximising clinical trial data from one patient sample, is key to delivering these solutions at speed.
Illumina discuss how they can gain speed in clinical development by avoiding bridging studies while Almac demonstrate how we deliver diagnostic testing utilising cutting edge genomic panels & providing tailored support at clinical sites through our global footprint of CLIA and CAP certified laboratories.
Senior Director, Companion Diagnostic (CDx) Partnering, Illumina
Dr Leeona Galligan
VP of UK Operations, Almac
Shared with kind permission from IlluminaView Resource
Your global partner for biomarker discovery, development & commercialisation.
We offer a range of genomics platform and chemistry options, alongside expert data sciences support and a full sample management service.
Clinical Trial Assays
Comprehensive development, validation & delivery service for research and clinical use assays from our global clinical laboratories in USA, Europe and APAC.
A collaborative Companion Diagnostic partnership approach with a deep understanding of client needs. We offer CDx development, manufacture & commercialisation services.